[Centrally acting muscle relaxant activities of 2-methyl-3-pyrrolidinopropiophenone derivatives]. 1987

M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura

UI MeSH Term Description Entries
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008297 Male Males
D009125 Muscle Relaxants, Central A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) Centrally Acting Muscle Relaxants,Central Muscle Relaxants,Relaxants, Central Muscle
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D011427 Propiophenones Propiophenone (ethyl phenyl ketone, structural formula C6H5COCH2CH3) and its derivatives. They are commonly used in perfumes and pharmaceuticals.
D003655 Decerebrate State A condition characterized by abnormal posturing of the limbs that is associated with injury to the brainstem. This may occur as a clinical manifestation or induced experimentally in animals. The extensor reflexes are exaggerated leading to rigid extension of the limbs accompanied by hyperreflexia and opisthotonus. This condition is usually caused by lesions which occur in the region of the brainstem that lies between the red nuclei and the vestibular nuclei. In contrast, decorticate rigidity is characterized by flexion of the elbows and wrists with extension of the legs and feet. The causative lesion for this condition is located above the red nuclei and usually consists of diffuse cerebral damage. (From Adams et al., Principles of Neurology, 6th ed, p358) Decerebrate Posturing,Decorticate Rigidity,Decorticate State,Rigidity, Decerebrate,Rigidity, Decorticate,Decerebrate Posturings,Decerebrate Rigidity,Decerebrate States,Decorticate Rigidities,Decorticate States,Posturing, Decerebrate,Posturings, Decerebrate,Rigidities, Decorticate,State, Decerebrate,States, Decerebrate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D012890 Sleep A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility. Sleep Habits,Sleeping Habit,Sleeping Habits,Habit, Sleep,Habit, Sleeping,Habits, Sleep,Habits, Sleeping,Sleep Habit
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
March 1987, Arzneimittel-Forschung,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
February 1987, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
September 1968, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
January 2006, CNS drug reviews,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
September 1975, Neuropharmacology,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
May 1966, The Journal of pharmacy and pharmacology,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
March 1983, Journal of pharmacobio-dynamics,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
November 1974, Archives internationales de pharmacodynamie et de therapie,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
March 1998, General pharmacology,
M Yamazaki, and Y Aoki, and H Kato, and Y Ito, and H Kontani, and R Koshiura
February 1970, British journal of pharmacology,
Copied contents to your clipboard!